OMX-0407 (Oncomatryx)

OMX-0407 is a first-in-class antibody-drug conjugate (ADC) developed by Oncomatryx Biopharma, designed to target the tumor microenvironment rather than the tumor cells directly. It consists of a humanized monoclonal antibody targeting Fibroblast Activation Protein alpha (FAPα), which is highly and selectively expressed on the surface of Cancer-Associated Fibroblasts (CAFs) in the stroma of many solid tumors, including non-squamous non-small cell lung cancer (NSCLC) and pancreatic cancer. The antibody is conjugated to a potent cytotoxic maytansinoid payload (DM4) via a cleavable SPDB linker. Upon binding to FAP and internalization into CAFs, the payload is released, leading to the depletion of the tumor stroma, inhibition of tumor growth, and potentially inducing a bystander effect on neighboring malignant cells. OMX-0407 is currently being evaluated in Phase 1 clinical trials for advanced solid tumors.

Other names

anti-FAP ADCFAP-targeted antibody-drug conjugateanti-fibroblast activation protein antibody-drug conjugate